Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391793 | 1.00 | NR1H2 (0.35) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL16391779 | 0.92 | GRIN2B (0.34) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL16391534 | 0.92 | GRIN2B (0.34) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL29825519 | 0.88 | NR1H2 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL18378137 | 0.88 | NR1H2 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL30646636 | 0.87 | NR1H2 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL22203885 | 0.87 | NR1H2 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL8386681 | 0.87 | NR1H2 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL30646546 | 0.82 | HSD11B1 (0.33) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL4243085 | 0.81 | NR1H2 (0.40) | NR1H2EPHX2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238285-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238285-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20220233525-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| US-11213523-B2 | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3252053-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200215062-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10456395-B2 | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190134028-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3252053-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3019499-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170128444-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128444-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9458159-B2 | Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458159-B2 | Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015006733-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456395-B2 | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | IFNAR1, CCR5, ZC3HAV1 | NR1H2 733/4885EPHX2 3463/4885CHRM2 326/4885 |
| US-20170128444-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, CCND3, CCR5 | NR1H2 2135/4885EPHX2 4268/4885CHRM2 73/4885 |
| US-20240238285-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CCND3, PRCP, ZC3HAV1 | NR1H2 1825/4885EPHX2 4563/4885CHRM2 94/4885 |
| US-20190134028-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CCND3, PRCP, ZC3HAV1 | NR1H2 1825/4885EPHX2 4563/4885CHRM2 94/4885 |
| US-20220233525-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CCND3, PRCP, ZC3HAV1 | NR1H2 1825/4885EPHX2 4563/4885CHRM2 94/4885 |
| US-20200215062-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CCND3, PRCP, ZC3HAV1 | NR1H2 1825/4885EPHX2 4563/4885CHRM2 94/4885 |
| US-11213523-B2 | Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections | PYM1, CD4, CCR5 | NR1H2 1569/4885EPHX2 2472/4885CHRM2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.